How big is Puma Biotechnology, Inc.?

As of Jun 18, Puma Biotechnology, Inc. has a market capitalization of 170.26 million, with net sales of 232.71 million and net profit of 38.06 million over the latest four quarters. Shareholder's funds are 92.12 million, and total assets are 214.75 million as of Dec 24.

As of Jun 18, Puma Biotechnology, Inc. has a market capitalization of 170.26 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 232.71 million, while the sum of Net Profit for the same period is 38.06 million.<BR><BR>As of Dec 24, the reporting period for the balance sheet shows Shareholder's Funds at 92.12 million and Total Assets at 214.75 million.

What does Puma Biotechnology, Inc. do?

Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing cancer treatments, with a market cap of $170.26 million and recent net sales of $46 million. Key financial metrics include a P/E ratio of 5.00 and a return on equity of 39.20%.

Overview: <BR>Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 46 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 3 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 170.26 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 5.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.32 <BR>Return on Equity: 39.20% <BR>Price to Book: 1.75<BR><BR>Contact Details: <BR>Address: 10880 Wilshire Blvd Ste 2150, LOS ANGELES CA: 90024-4106 <BR>Tel: 1 424 2486500 <BR>Fax: 1 424 2486501 <BR>Website: https://www.pumabiotechnology.com/

Should I buy, sell or hold Puma Biotechnology, Inc.?

Who are in the management team of Puma Biotechnology, Inc.?

As of March 2022, the management team of Puma Biotechnology, Inc. includes Alan Auerbach (Chairman, President, and CEO), Jay Moyes (Lead Independent Director), Brian Stuglik, Ann Miller, Michael Miller, and Hugh O'Dowd (all Independent Directors). They oversee the company's strategic direction and operations.

As of March 2022, the management team of Puma Biotechnology, Inc. includes the following individuals:<BR><BR>- Mr. Alan Auerbach: Chairman of the Board, President, and Chief Executive Officer<BR>- Mr. Jay Moyes: Lead Independent Director<BR>- Mr. Brian Stuglik: Director<BR>- Dr. Ann Miller: Independent Director<BR>- Mr. Michael Miller: Independent Director<BR>- Mr. Hugh O Dowd: Independent Director<BR><BR>This team is responsible for overseeing the strategic direction and operations of the company.

Is Puma Biotechnology, Inc. overvalued or undervalued?

As of July 7, 2025, Puma Biotechnology, Inc. is considered very attractive due to its undervalued status, evidenced by a low P/E ratio of 5, a Price to Book Value of 1.90, and an EV to EBITDA ratio of 3.15, despite recent short-term underperformance compared to the S&P 500.

As of 7 July 2025, the valuation grade for Puma Biotechnology, Inc. has moved from attractive to very attractive, indicating a strong improvement in its valuation outlook. The company appears to be undervalued, supported by a P/E ratio of 5, a Price to Book Value of 1.90, and an EV to EBITDA ratio of 3.15, all of which suggest that the stock is trading at a discount relative to its earnings and assets.<BR><BR>In comparison to its peers, Puma Biotechnology's P/E ratio of 4.74 is significantly lower than Zevra Therapeutics, Inc. at 7.44, indicating a more favorable valuation. Additionally, the PEG ratio of 0.04 highlights its growth potential relative to its price, further reinforcing the undervaluation thesis. Notably, while Puma's stock has underperformed the S&P 500 in the short term, returning -9.69% over the past month compared to the index's 2.33%, it has delivered impressive returns year-to-date at 48.20%, outpacing the S&P 500's 12.22%.

Is Puma Biotechnology, Inc. technically bullish or bearish?

As of August 8, 2025, Puma Biotechnology, Inc. shows a bullish technical trend with strong momentum indicators, despite some mixed signals from the weekly Dow Theory and KST.

As of 8 August 2025, the technical trend for Puma Biotechnology, Inc. has changed from mildly bullish to bullish. The weekly MACD and Bollinger Bands are bullish, while the daily moving averages also indicate a bullish stance. However, the weekly Dow Theory shows a mildly bearish signal, and the KST is bullish on a weekly basis but only mildly bullish monthly. The stock has performed well year-to-date with a return of 48.20%, significantly outperforming the S&P 500's 12.22% return. Overall, the current technical stance is bullish, with strength indicated by the positive momentum in MACD and Bollinger Bands, despite some mixed signals from other indicators.